Coronary angiogenesis during experimental hypertension: Is it reversible?

Journal of Research in Medical Sciences

Volumn 16, Issue 3, 2011, Pages 269-275

  Zarei, Mohammad ^a,b   Khazaei, Majid ^a   Sharifi, Mohammad Reza ^a   Pourshanazari, Ali Asghar ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis inhibitor; Coronary vessels; Hypertension; Vascular endothelial growth factor receptor 1

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; CAPILLARY DENSITY; CLIP; CONTROLLED STUDY; CORONARY ANGIOGENESIS; HYPERTENSION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT;

EID: 79955490430     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ylä-Herttuala S, Rissanen TT, Vajanto I, Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007; 49(10): 1015-26.
2. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18(1): 4-25.
3. Lieb W, Safa R, Benjamin EJ, Xanthakis V, Yin X, Sullivan LM, et al. Vascular endothelial growth factor, its soluble receptor, and hepatocyte growth factor: clinical and genetic correlates and association with vascular function. Eur Heart J 2009; 30(9): 1121-7.
4. Wu FT, Stefanini MO, Mac Gabhann F, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 2010;14(3):528-52.
5. Félétou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol 2006; 291(3): H985-1002.
6. Touyz RM. Intracellular mechanisms involved in vascular remodelling of resistance arteries in hypertension: role of angiotensin II. Exp Physiol 2005; 90(4): 449-55.
7. Humar R, Zimmerli L, Battegay E. Angiogenesis and hypertension: an update. J Hum Hypertens 2009; 23(12): 773-82.
8. le Noble FA, Stassen FR, Hacking WJ, Struijker Boudier HA. Angiogenesis and hypertension. J Hypertens 1998; 16(11): 1563-72.
9. Emanueli C, Salis MB, Stacca T, Gaspa L, Chao J, Chao L, et al. Rescue of impaired angiogenesis in spontaneously hypertensive rats by intramuscular human tissue kallikrein gene transfer. Hypertension 2001; 38(1): 136-41.
10. Belgore FM, Lip GY, Bareford D, Wadley M, Stonelake P, Blann AD. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in haematological cancers: a comparison with breast cancer. Am J Hematol 2001; 66(1): 59-61.
11. Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 1991; 17(5): 707-19.
12. Nyström HC, Jia J, Johansson M, Lambert G, Bergström G. Neurohormonal influences on maintenance and reversal of two-kidney one-clip renal hypertension. Acta Physiol Scand 2002; 175(3): 245-51.
13. Göthberg G, Thorén P. Sympathetic inhibition after surgical reversal of renovascular hypertension in rats. Role of vagal nerves. Acta Physiol Scand 1986; 126(3): 397-404.
14. Sane DC, Anton L, Brosnihan KB. Angiogenic growth factors and hypertension. Angiogenesis 2004; 7(3): 193-201.
15. Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management. Am J Hypertens 2003; 16(1): 11-20.
16. le Noble JL, Tangelder GJ, Slaaf DW, van Essen H, Reneman RS, Struyker-Boudier HA. A functional morphometric study of the cremaster muscle microcirculation in young spontaneously hypertensive rats. J Hypertens 1990; 8(8): 741-8.
17. Murfee WL, Schmid-Schönbein GW. Chapter 12. Structure of microvascular networks in genetic hypertension. Methods Enzymol 2008; 444: 271-84.
18. Hernández N, Torres SH, Finol HJ, Vera O. Capillary changes in skeletal muscle of patients with essential hypertension. Anat Rec 1999; 256(4): 425-32.
19. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376(6535): 66-70.
20. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006; 9(4): 225-30.
21. Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, et al. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]). Am J Cardiol 2003; 92(4): 400-5.
22. Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR, et al. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis 2009; 206(1): 265-9.